|
Viread
(tenofovir)
Articles on Tenofovir (Viread)
Tenofovir
Improves Outcomes of HBV Acute-on-Chronic Liver Failure
5-10-2011
HBV
Genotype Predicts HBeAg Seroconversion on Tenofovir
4-12-2011
Tenofovir
and Entecavir Are Safe and Effective in Hepatitis B Patients with
Decompensated Cirrhosis
1-18-2011
Effectiveness
and Safety of Tenofovir in Real-world
Clinical Practice
11-23-2010
Tenofovir
(Viread) Maintains HBV Suppression without Resistance
for 4 Years
11-02-2010
No
Resistance to Tenofovir Disoproxil Fumarate
(TDF) Detected Following up to 192 Weeks of Treatment
in Subjects Mono-Infected with Chronic Hepatitis B Virus
11-02-2010
Long
Term (4 Year) Effi cacy and Safety of Tenofovir
Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive
Patients (HBeAg+) with Chronic Hepatitis B (Study 103)
11-02-2010
4 Year
Efficacy of TenofovirDisoproxilFumarate
(TDF) in Chronic Hepatitis B Patients with High Viral
Load (HBV DNA .9 log10copies/mL)
11-02-2010
Four
Years Effi cacy and Safety of Tenofovir
Disoproxil Fumarate (TDF) in Asians with HBeAg-Positive
and HBeAg-Negative Chronic Hepatitis B
11-02-2010
HBV
rtN236T Mutant Subpopulations Respond Like Wild-Type During Tenofovir
DF (TDF) Monotherapy or Combination Therapy with Emtricitabine
(FTC): an Evaluation of Early Viral Load Decay Kinetics
11-02-2010
TenofovirDisoproxilFumarate
(TDF) Versus EmtricitabinePlus TDF (FTC/TDF) for Treatment
of Chronic Hepatitis B (CHB) In Patients with Persistent Viral Replication
Receiving AdefovirDipivoxil: Final Week 168 Results
11-02-2010
Meta-analysis Finds Tenofovir
and Entecavir Are Most Effective Antiviral Drugs for Chronic Hepatitis
B
8-24-2010
How Long Do Chronic Hepatitis B
Patients Need to be Treated
to Sustain HBeAg Seroconversion?
6-25-2010
Tenofovir (Viread) Effective
for Treatment of Chronic Hepatitis B Patients with Suboptimal Response
to Adefovir (Hepsera)
5-7-2010
Tenofovir
(Viread) Demonstrates High Barrier to Resistance over
3 Years in Chronic Hepatitis B Patients
4-23-2010
Tenofovir
(Viread) Produces Long-term Response in Chronic Hepatitis
B Patients with Prior Treatment Failure
1-15-2010
Tenofovir
(Viread) Produces
Good HBV Suppression in Chronic Hepatitis B Patients with Resistance
to Adefovir (Hepsera)
11/24/09
A
Phase 2, Double-Blind, Randomized Study Comparing The Safety of
Tenofovir Disoproxil Fumarate (TDF), Emtricitabine
Plus TDF (Truvada, TVD) and Entecavir (ETV) in Subjects with Decompensated
Chronic Hepatitis B Liver Disease
11/03/09
Tenofovir
(Viread) Regimens Are Effective and Well-tolerated in
Chronic Hepatitis B Patients with Decompensated Liver Disease
11/03/09
Entecavir
(Baraclude) and
Tenofovir (Viread) Rescue Therapy for Chronic Hepatitis
B Patients with Advanced Fibrosis and Prior Treatment Failure
11/03/09
Long-term
Follow-up Evaluation of the Efficacy and Safety of Tenofovir
Disoproxil Fumarate (TDF) in a European Multicenter (Nucleos(t)ide
Experienced) Hepatitis B Virus HBV-infected Cohort
11/03/09
Tenofovir
(TDF) Is Effective In Lamivudine (LAM) Resistant Chronic
Hepatitis B Patients Who Harbour rtA194T At Baseline
11/03/09
Tenofovir
Disoproxil Fumarate for patients with chronic hepatitis
B who have previously failed Lamivudine
and
Adefovir: effects of baseline sequence mutations on virological
response.
11/03/09
In
vitro susceptibility of HBV strains isolated from HIV-HBV Coinfected
patients with delayed response to Tenofovir
DF
11/03/09
Tenofovir
Disoproxil Fumarate-Containing Regimens in Pregnancy:
Report From the Antiretroviral Pregnancy Registry
11/03/09
Three
Years of Tenofovir Disoproxil Fumarate
(TDF) Treatment in HBeAg-Positive Patients (HBeAg+) With
Chronic Hepatitis B (Study 103)
11/03/09
In
Vitro Tenofovir Sensitivity
of HBV Populations from Clinical Specimens Containing rtA181T/V
and/or rtN236T
11/03/09
Three
Years Effi cacy and Safety of Tenofovir
Disoproxil Fumarate (TDF) in Asians with HBeAg-Positive
and HBeAg-Negative Chronic Hepatitis B
11/03/09
Three
Years of Tenofovir Disoproxil Fumarate
(TDF) Treatment in HBeAg-Negative Patients with Chronic
Hepatitis B (Study 102)
11/03/09
Resistance
Surveillance for up to 144 Weeks in HBeAg+ and HBeAg- Hepatitis
B Patients Treated with Tenofovir DF
Showed No Relationship Between Virologic Breakthrough and Emergence
of Genotypic Changes in HBV Polymerase
11/03/09
Long-term Studies
Show Tenofovir (Viread) Safety
and Efficacy Is Sustained at 3 Years in HBeAg Positive and Negative
Hepatitis B Patients
11/03/09
Should
Entecavir (Baraclude) and Tenofovir (Viread)
Be First-line Treatment for Chronic Hepatitis B?
6/05/09
Tenofovir
(Viread) Is Similarly Effective in Chronic Hepatitis
B Patients Regardless of Liver Cirrhosis Status
5/08/09
Addition
of Emtricitabine (Emtriva) Does Not Improve Response to Tenofovir (Viread) for Chronic Hepatitis
B
5/05/09
Evolution
of Viral Load and Genome Sequence in a Clinical Trial of Tenofovir/Emtricitabine Combination Versus
Tenofovir Monotherapy for Patients with Previous Adefovir
Dipivoxil Failure
4/24/09
Tenofovir Disoproxil
Fumarate (TDF) Versus Emtricitabine Plus TDF (FTC/TDF)
for Treatment of Chronic Hepatitis B (CHB) in Patients with Persistent
Viral Replication Receiving Adefovir Dipivoxil
4/24/09
Characteristics of HBeAg-Positive Patients
with HBsAg Loss/Seroconversion Following Treatment with Tenofovir
Disoproxil Fumarate (TDF)
4/24/09
Safety and Efficacy of 96 Weeks of Tenofovir Disoproxil Fumarate
Therapy in Lamivudine Experienced Patients
4/24/09
Safety and Tolerability of 96 Weeks of Tenofovir
Disoproxil Fumarate (TDF) Treatment in HBeAg Negative
and Positive Patients Infected with Chronic Hepatitis B (CHB)
4/24/09
Two Years Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF)
in Patients with HBV-Induced Cirrhosis
4/24/09
|
